# To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct07454187/  
OnCo record `nct07454187` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SG2918 in multiple myeloma, run by Hangzhou Sumgen Biotech Co., Ltd., now recruiting.

## Summary

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT07454187 by Hangzhou Sumgen Biotech Co., Ltd., with 40 participants planned, started 2026-04-16 and due to reach its primary completion in 2027-09-30. Interventions recorded: SG2918.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07454187
- Phase: 1/2
- Setting: A Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG2918 for Injection in Patients With Relapsed/Refractory Multiple Myeloma
- Sponsor: Hangzhou Sumgen Biotech Co., Ltd.
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07454187: https://clinicaltrials.gov/study/NCT07454187

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- companies: [Hangzhou Sumgen Biotech](https://onco.cc/companies/hangzhou-sumgen-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct07454187.json